세계의 디프테리아 시장 보고서(2025년)
Diphtheria Global Market Report 2025
상품코드 : 1824645
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,493,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,386,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,279,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

박테리아 감염의 유행 증가는 앞으로 수년간 디프테리아 시장의 성장을 가속할 것으로 예측됩니다. 박테리아 감염은 박테리아가 신체에 침입하여 직접 감염이나 독소 생산으로 질병을 유발함으로써 발생합니다. 심각한 박테리아 감염인 디프테리아는 코리네박테리움 디프테리아(Corynebacterium diphtheriae)의 균주에 의해 유발되어 면역 시스템을 약화시키고 박테리아의 증식을 촉진합니다. 예를 들어 2024년 9월 영국 정부 웹사이트인 GOV.UK에 따르면 잉글랜드의 NHS 급성 트러스트에서는 2022-2023 회계연도 중에 3만 8,757건의 대장균균증이 보고되었으며, 그 중 7,881건(20.3%)이 병원 발병 감염증이었습니다. 박테리아 감염은 증가의 길을 따라가고 있으며, 디프테리아 시장도 그에 따라 성장이 예상됩니다.

디프테리아 시장은 예방접종 프로그램 증가 추세에 힘입어 성장을 이루고 있습니다. 예방 접종 프로그램은 예방 접종으로 예방 가능한 질병으로부터 개인을 보호하기 위한 일련의 서비스를 포함합니다. 이 프로그램은 백신으로 예방 가능한 질병으로 인한 질병, 장애 및 사망을 억제하는 것을 목표로 합니다. 디프테리아 및 기타 백신은 다양한 국가 및 지역에 걸친 예방 접종 이니셔티브를 통해 개인에게 일상적으로 투여됩니다. 예를 들어, 2023년 7월 유엔 국제 아동 비상 기금(UNICEF)은 디프테리아, 파상풍, 백일해(DTP3)의 세 번째 접종률이 세계적으로 상승했다고 보고했습니다. 이 접종률은 예방접종 노력으로 2021년 81%에서 2022년 84%로 상승했습니다. 그 결과 예방접종 프로그램의 융성이 디프테리아 시장의 성장을 지원하고 있습니다.

디프테리아 시장에 종사하는 기업은 시장 포지션을 유지하기 위해 적극적으로 기술 혁신을 실시하고 FDA의 승인을 얻고 있습니다. 2022년 10월 영국 제약 바이오테크놀러지 기업인 GlaxoSmithKlinePLC가 미국 식품의약국(FDA)에서 BOOSTRIX(파상풍 톡소이드, 환원형 디프테리아 톡소이드, 백일해 백신, 흡착형; Tdap)의 승인을 취득했다고 발표했습니다. 이 승인은 생후 2개월 이하의 유아의 백일해를 예방하기 위해 임신 3기에서 예방접종을 허가하는 것입니다. 임산부에게 Tdap 백신을 접종함으로써 어머니에서 아이로의 방어 항체 전환은 생후 몇 개월의 신생아에게 백일해에 대한 최적의 방어를 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

Diphtheria is a bacterial disease caused by strains of bacteria known as Corynebacterium diphtheriae. These bacteria produce a toxin that primarily affects the mucous membranes of the throat and nose and can also impact other parts of the body, particularly in severe cases. Diphtheria is characterized by symptoms such as throat discomfort, weakness, fever, swollen neck glands, breathing difficulties due to the blockage of tissues in the nose and throat, and swallowing difficulties.

The main types of infections related to diphtheria encompass diphtheria, skin diphtheria, and others. Diphtheria is a dangerous bacterial infection that can affect the tonsils, nose, throat, and/or skin and is caused by toxin-producing Corynebacterium diphtheriae bacteria. Diagnosis typically involves a physical examination and throat culture and can be confirmed with the use of antibiotics, antitoxins, and other treatment approaches. Diphtheria-related products and treatments are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies. These products and therapies are employed in a range of healthcare settings, including hospitals, homecare, specialty clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The diphtheria market research report is one of a series of new reports from The Business Research Company that provides diphtheria market statistics, including diphtheria industry global market size, regional shares, competitors with a diphtheria market share, detailed diphtheria market segments, market trends and opportunities and any further data you may need to thrive in the diphtheria industry. This diphtheria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diphtheria market size has grown strongly in recent years. It will grow from $8.91 billion in 2024 to $9.39 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to vaccine development, immunization campaigns, increased awareness, healthcare infrastructure.

The diphtheria market size is expected to see strong growth in the next few years. It will grow to $12.1 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to emerging outbreaks, booster vaccination programs, global travel and migration, public health preparedness. Major trends in the forecast period include combination vaccines, telemedicine for vaccination, vaccine equity initiatives, public-private partnerships.

The forecast of 6.5% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. public health by increasing the cost of diphtheria antitoxin and DTaP vaccine components sourced from Canada and Germany, thereby risking immunization gaps and elevating emergency preparedness costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of bacterial infections is expected to drive the growth of the diphtheria market in the coming years. Bacterial infections occur when bacteria invade the body, causing illness either through direct infection or by producing toxins. Diphtheria, a serious bacterial infection, is caused by strains of Corynebacterium diphtheriae, which weaken the immune system and promote bacterial growth. For example, in September 2024, according to GOV.UK, a UK government website, NHS acute trusts in England reported 38,757 cases of E. coli bacteremia during the fiscal year 2022-2023, with 7,881 (20.3%) of these cases being hospital-onset infections. As bacterial infections continue to rise, the diphtheria market is expected to grow accordingly.

The diphtheria market is experiencing growth, largely underpinned by the upward trajectory of immunization programs. Immunization programs encompass a suite of services aimed at safeguarding individuals against vaccine-preventable illnesses by delivering vaccinations. These programs are designed to curtail sickness, disability, and mortality stemming from vaccine-preventable maladies. Diphtheria and other vaccines are routinely administered to individuals through immunization initiatives spanning different countries and regions. For instance, in July 2023, the United Nations International Children's Emergency Fund (UNICEF) reported an uptick in global coverage for the third dose of the Diphtheria, Tetanus, Pertussis (DTP3) vaccination. This coverage increased from 81% in 2021 to 84% in 2022 through immunization efforts. Consequently, the escalating prominence of immunization programs is a propellant behind the growth of the diphtheria market.

Companies engaged in the diphtheria market are actively innovating and securing FDA approvals to maintain their market positions. A prime example of such innovation occurred in October 2022 when GlaxoSmithKline PLC, a U.K.-based pharmaceutical and biotechnology firm, announced that the U.S. Food and Drug Administration (FDA) granted approval for BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, adsorbed; Tdap). This approval permits immunization during the third trimester of pregnancy to prevent pertussis (whooping cough) in infants under two months old. Administering the Tdap vaccine to pregnant women confers optimal protection against whooping cough for newborns during their initial months of life through the transference of protective antibodies from mother to child.

In December 2022, Pharmaniaga LifeScience Sdn Bhd (PLS), a pharmaceutical company headquartered in Malaysia, initiated a collaborative research agreement with BioNet-Asia Co. Ltd. (BioNet) for an undisclosed sum. This partnership focuses on the research and development of a 6-in-1 Hexavalent Vaccine targeting diseases like diphtheria (DT), tetanus (TT), pertussis (aP), poliomyelitis (IPV), Haemophilus influenzae type b (Hib), and hepatitis B (Hep-B). The collaboration is in line with Pharmaniaga's objective to establish the world's first Halal vaccine and insulin manufacturing facilities. This initiative aims to reduce Malaysia's reliance on imported life-saving vaccines and insulin, fostering the nation's goal of vaccine self-sufficiency. BioNet-Asia Co. Ltd. is a Thailand-based company specializing in the development and manufacturing of life-saving vaccines against bacterial infections, including diphtheria and tetanus.

Major companies operating in the diphtheria market are Pfizer Inc., Johnson & Johnson Co, Roche Holding AG, Merck & Co Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., Serum Institute of India, Novavax Inc., Sinovac Biotech Ltd., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Bharat Biotech International Limited, CureVac AG, Inovio Pharmaceuticals Inc., The Native Antigen Company.

Asia-Pacific was the largest region in the diphtheria market in 2024. The regions covered in diphtheria report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diphtheria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diphtheria market consists of revenues earned by entities by providing services such as consultation, diagnosis and treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The diphtheria market also includes the sales of medications such as vaccines, antibiotics and antitoxins. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diphtheria Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diphtheria market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for diphtheria ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diphtheria market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Diphtheria Market Characteristics

3. Diphtheria Market Trends And Strategies

4. Diphtheria Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Diphtheria Growth Analysis And Strategic Analysis Framework

6. Diphtheria Market Segmentation

7. Diphtheria Market Regional And Country Analysis

8. Asia-Pacific Diphtheria Market

9. China Diphtheria Market

10. India Diphtheria Market

11. Japan Diphtheria Market

12. Australia Diphtheria Market

13. Indonesia Diphtheria Market

14. South Korea Diphtheria Market

15. Western Europe Diphtheria Market

16. UK Diphtheria Market

17. Germany Diphtheria Market

18. France Diphtheria Market

19. Italy Diphtheria Market

20. Spain Diphtheria Market

21. Eastern Europe Diphtheria Market

22. Russia Diphtheria Market

23. North America Diphtheria Market

24. USA Diphtheria Market

25. Canada Diphtheria Market

26. South America Diphtheria Market

27. Brazil Diphtheria Market

28. Middle East Diphtheria Market

29. Africa Diphtheria Market

30. Diphtheria Market Competitive Landscape And Company Profiles

31. Diphtheria Market Other Major And Innovative Companies

32. Global Diphtheria Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diphtheria Market

34. Recent Developments In The Diphtheria Market

35. Diphtheria Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기